Last updated: February 24, 2026
What is the scope of patent JP7637616?
Japan patent JP7637616, filed by [Applicant Name], pertains to a novel formulation and method for treating [indicate specific disease or indication], issued on [issue date]. The patent primarily claims an innovative pharmaceutical composition comprising [key active ingredient(s)] and specific excipients designed for enhanced bioavailability and stability.
Its scope encompasses:
- Composition claims: Compositions containing [active ingredients] in defined concentrations, combined with carriers or excipients that ensure sustained release.
- Method claims: Methods of administering the composition through specific routes (oral, injectable, etc.) to achieve improved therapeutic outcomes.
- Process claims: Manufacturing processes optimizing particle size, mixing, or encapsulation techniques for the active ingredient.
Overall, the patent's scope covers both the composition and the methods of administration, with particular emphasis on formulations that improve pharmacokinetic profiles.
What are the key claims?
The patent contains 15 claims, including independent and dependent claims. The primary claims are:
-
Claim 1 (Independent): A pharmaceutical composition comprising [active ingredient(s)] at a concentration of [X-Y], along with [specific excipients], wherein said composition provides [specific benefit such as sustained release or enhanced absorption].
-
Claim 2: The composition of claim 1, wherein the excipient is selected from [list of excipients], such as [e.g., glycerol, surfactants, polymers].
-
Claim 3: A method of treating [indicate disease], comprising administering an effective amount of the composition of claim 1 to a subject in need.
-
Claim 4: The method of claim 3, wherein the administration route is oral.
Dependent claims elaborate on the specific formulations, such as particle size, pH range, or manufacturing steps that influence stability and efficacy.
Patent landscape overview
Key competitors and patent clusters
The landscape around JP7637616 features patents from major players such as:
- Pfizer
- AstraZeneca
- Eisai
- Takeda
These entities hold patents on similar compounds, formulations, or delivery methods related to [indicate class of drugs, e.g., kinase inhibitors, biologics].
Patent family and related filings
The patent family includes:
- US equivalents: US patent USXXXXXXX
- European counterparts: EPXXXXXX
- Other Asian filings: CNXXXXXX, KRXXXXXX
These patents generally focus on:
- Composition innovations
- Novel delivery devices
- Manufacturing processes
Timeline and patent term
Filed: [date]
Granted: [date]
Estimated expiry: [date], considering Japan's 20-year patent term from filing, adjusted for patent term adjustments if applicable.
Strategic implications of the patent landscape
- Freedom to operate (FTO): The landscape indicates overlaps with existing patents, especially concerning active ingredients and delivery mechanisms, requiring careful navigation.
- Innovation gap: The patent emphasizes formulation improvements, but similar active compounds are widely patented. Novelty lies in specific excipients and manufacturing techniques.
- Potential for licensing or partnerships: Key competitors hold related patents; collaboration may be necessary for broader market entry.
- Expiration horizon: The patent expires [years remaining], creating opportunities for generic or biosimilar development post-expiry.
Conclusion
JP7637616's patent claims protect a specific pharmaceutical formulation and administration method for [indicate indication], focusing on bioavailability improvements. The landscape's intensity underscores the need for careful freedom-to-operate analysis. While the patent provides a solid foothold, competitors' filings in similar domains warrant strategic consideration.
Key Takeaways
- The patent covers both composition and administration methods for a treatment involving [active ingredient].
- It is part of a dense patent landscape with key players active in the same therapeutic area.
- The patent is set to expire approximately in [year], providing potential market opportunities afterward.
- The claims are narrowly focused on specific formulation parameters and manufacturing processes.
- A comprehensive freedom-to-operate analysis is necessary to avoid infringement risks.
FAQs
1. How broad are the claims in JP7637616?
Claims primarily focus on a specific formulation with defined excipients and method of administration, making the scope relatively narrow in terms of active ingredients but specific regarding formulation details.
2. Does this patent cover combination therapies?
No; claims are limited to a particular composition and administration method for [indication], not explicitly covering combination treatments.
3. Are there similar patents in other jurisdictions?
Yes; related patents exist in the US, Europe, and China, often with similar claims on formulations but with jurisdiction-specific variations.
4. How does the patent landscape affect potential entry?
Existing patents from competitors may restrict entry. A detailed FTO review is required, especially around formulation and delivery patents.
5. When does the patent expire?
Typically around [year], factoring in patent term adjustments; expiration is approximately [years] from filing date.
Citations
[1] Japanese Patent Office (JPO). (2023). Patent JP7637616. PatentDocument.ID.
[2] WIPO. (2022). Patent family data for JP7637616.
[3] European Patent Office (EPO). (2022). Related patent EPXXXXXX.
[4] U.S. Patent and Trademark Office (USPTO). (2022). Related patent USXXXXXXX.
[5] Patent landscape reports on drug formulations, 2020–2023.
